


PHARMACEUTICAL 2020

Evofem Biosciences Inc. Rank 326 of 358





PHARMACEUTICAL 2020

Evofem Biosciences Inc. Rank 326 of 358

The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Evofem Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 259% points.

The company's Economic Capital Ratio, given in the ranking table, is -260%, being 296% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	26,421
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,659
Liabilities, Non-Current	0
Other Assets	1,480
Other Compr. Net Income	0
Other Expenses	4.0
Other Liabilities	0
Other Net Income	-27,287
Other Revenues	0
Property and Equipment	394
Research and Development	22,230
Selling, General and Administrative Expense	30,512

Output Variable	Value in 1000 USD
Assets	28,295
Liabilities	12,659
Expenses	52,746
Revenues	0
Stockholders Equity	15,636
Net Income	-80,033
Comprehensive Net Income	-80,033
Economic Capital Ratio	-260%

